Reno

Renovion is a clinical-stage biopharmaceutical company dedicated to advancing therapies that restore lung health by addressing mucus accumulation, chronic inflammation, and bacterial infection. The company's lead product, ARINA-1, is a novel nebulized therapy designed to clear mucus and improve lung function in patients with orphan chronic inflammatory lung diseases. Renovion is currently focusing its clinical development on high-unmet-need populations, including lung transplant recipients and patients with non-cystic fibrosis bronchiectasis (NCFBE). By restoring mucociliary clearance and reducing the inflammatory burden, Renovion aims to significantly improve the quality of life and clinical outcomes for individuals suffering from severe respiratory conditions.